ASCO22
Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting.
The study included adults with treatment-naïve and relapsed/refractory CLL or small lymphocytic leukemia.
The phase I/II study included patients with relapsed/refractory CLL or MCL who received two or more prior systemic therapies.
Advertisement
Updated findings from the ASCEND study were presented at the 2022 ASCO Annual Meeting.
DIAMOND-01 determined a recommended dose of SEL24/MEN1703 125 mg orally once daily for 14 days during a 21-day cycle.
Belantamab mafodotin is a BCMA targeted antibody drug conjugate approved for adult patients...
Advertisement
Median PFS and OS were 25.8 months (95% CI, 9.6-47.6) and 46.6 months (95% CI, 24.9-not estimable), respectively.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.